Neuropsychopharmacology

Descending projections from the medial habenula potently influence brainstem systems associated with reward and mood. Relatedly, the ventral, cholinergic segment of the nucleus has been linked to nicotine and cocaine addiction. Here we report that cocaine has no effect on baseline firing in the ventral medial habenula but entirely blocks the self-sustained activity initiated by endogenous acetylcholine. This effect was not altered by antagonists to dopamine receptors and thus presumably reflects a direct action on cholinergic receptors. Remarkably, cocaine had no effect on endogenous cholinergic activity in mice that had been extinguished from an induced cocaine preference. In all, the drug has potent effects, albeit through an exotic mode of action, on the medial habenula and these are eliminated by prior experience with the drug. These results describe a novel target for cocaine that is plausibly related to the psychological effects of the drug, and an unexpected consequence of earlier use.

Antipsychotic dosing regimens, commonly daily or via slow-release compounds, are designed to maintain steady-state plasma concentrations. They are guided by their plasma half-life that is typically in the range of several hours. This schedule contrasts with the slow time course of therapeutic efficacy, which often takes weeks to develop fully. This discrepancy led us to hypothesize that the effects of a single dose of an antipsychotic drug might be detectable well beyond the time window predicted by receptor occupancy. To test this, we administered a single dose of the antipsychotic drug clozapine to mice. We observed long-term behavioral effects and changes to cortical activity patterns up to several days after administration. Specifically, clozapine induced a decorrelation of activity in the dorsal cortex observable up to 9 days post administration. This effect was driven by a genetically and functionally distinct subset of layer 5 intratelencephalic neurons, possibly through a clozapine induced increase in the reliability of long-range inhibitory functional influence that exhibited a similar long-term change. Thus, our findings suggest that longer dosing intervals for antipsychotic drugs warrant clinical exploration.

The opioid epidemic is a rapidly evolving societal issue driven, in part, by a surge in synthetic opioid use. A rise in fentanyl use among pregnant women has led to a 40-fold increase in the number of perinatally-exposed infants in the past decade. These children are more likely to develop mood- and somatosensory-related conditions later in life, suggesting that fentanyl may permanently alter neural development. Here, we examined the behavioral and synaptic consequences of perinatal fentanyl exposure in adolescent male and female C57BL/6J mice and assessed the therapeutic potential of environmental enrichment to mitigate these effects. Dams were given ad libitum access to fentanyl (10 {micro}g/mL, per os) across pregnancy and until weaning (PD 21). Perinatally-exposed adolescent mice displayed hyperactivity (PD 45), enhanced sensitivity to anxiogenic environments (PD 46), and sensory maladaptation (PD 47) - sustained behavioral effects that were completely normalized by environmental enrichment (PD 21-45). Additionally, environmental enrichment normalized the fentanyl-induced changes in the frequency of miniature excitatory postsynaptic currents of layer 2/3 neurons in the primary somatosensory cortex (S1). We also demonstrate that fentanyl impairs short- and long-term potentiation in S1 layer 2/3 neurons which, instead, exhibit a sustained depression of synaptic transmission that is restored by environmental enrichment. On its own, environmental enrichment suppressed long-term depression of control S1 neurons from vehicle-treated mice subjected to standard housing conditions. These results demonstrate that the lasting effects of fentanyl can be ameliorated with a non-invasive intervention introduced during early development. Significance StatementIllicit use of fentanyl accounts for a large proportion of opioid-related overdose deaths. Children exposed to opioids during development have a higher risk of developing neuropsychiatric disorders later in life. Here, we employ a preclinical model of perinatal fentanyl exposure that recapitulates these long-term impairments and show, for the first time, that environmental enrichment can reverse deficits in somatosensory circuit function and behavior. These findings have the potential to directly inform and guide ongoing efforts to mitigate the consequences of perinatal opioid exposure.

Inhibiting the actin motor ATPase nonmuscle myosin II (NMII) with blebbistatin (Blebb) in the basolateral amgydala (BLA) depolymerizes actin, resulting in an immediate, retrieval-independent disruption of methamphetamine (METH)-associated memory. The effect is highly selective, as NMII inhibition has no effect in other relevant brain regions (e.g. dorsal hippocampus [dPHC], nucleus accumbens [NAc]), nor does it interfere with associations for other aversive or appetitive stimuli, including cocaine (COC). To investigate a potential source of this specificity, pharmacokinetic differences in METH and COC brain exposure were examined. Replicating METHs longer half-life with COC did not render the COC association susceptible to disruption by NMII inhibition. Therefore, transcriptional differences were next assessed. Comparative RNA-seq profiling in the BLA, dHPC and NAc following METH or COC conditioning identified crhr2, which encodes the corticotrophin releasing factor receptor 2 (CRF2), as uniquely upregulated by METH in the BLA. CRF2 antagonism with Astressin-2B (AS2B) had no effect on METH-associated memory after consolidation, allowing for determination of CRF2 influences on NMII-based susceptibility after METH conditioning. Pretreatment with AS2B occluded the ability of Blebb to disrupt an established METH-associated memory. Alternatively, the Blebb-induced, retrieval-independent memory disruption seen with METH was mimicked for COC when combined with CRF2 overexpression in the BLA and its ligand, UCN3 during conditioning. These results indicate that BLA CRF2 receptor activation during learning can prevent stabilization of the actin-myosin cytoskeleton supporting the memory, rendering it vulnerable to disruption via NMII inhibition. CRF2 represents an interesting target for BLA-dependent memory destabilization via downstream effects on NMII.

Ketamines rapid acting symptom relief make it a promising intervention for PTSD. However, the mechanisms driving its long-term efficacy over weeks and months remain poorly understood. This study investigated the short-and long-term impacts on gene expression of a six-week subanesthetic oral ketamine trial in 23 PTSD participants (9 males, 14 females). Peripheral Blood Mononuclear Cells (PBMCs) were collected at baseline, one week (short-term), and four weeks (long-term) post oral ketamine for RNA sequencing and transcriptome analysis. Differential expression analysis identified substantial and persistent transcriptomic changes over time, with 533 genes upregulated and 621 downregulated across timepoints. Notably, there was a 37% increase in differential gene expression between the short-and long-term responses, accompanied by a 6.5-fold rise in expression magnitude and an 8.8-fold enhancement in pathway activity. Pathway analysis emphasised critical immune and inflammatory pathways that appear to be modulated by ketamine, including interferon alpha/beta signalling (z = 4), IL-17 signalling pathway (z = 3.36), and cytokine storm signalling (z = 4.26), neutrophil degranulation (z = 6.0) and antimicrobial peptide signalling (z = 1.63) which differed across timepoints. The findings suggest a transition from short-term inflammation suppression and antimicrobial activity to long-term sustained immune regulation, inflammation remodulation and tissue repair. Key cytokines, chemokines, interferons and antimicrobial peptides included, IL-6, IL-1{beta}, IFI27, IL-10 signalling, CXCL8, SOCS1/3 and CAMP which represent central regulators of immune and inflammatory pathways. These molecular changes offer novel insights into the short-and long-term therapeutic potential of ketamine for PTSD and highlight avenues for precision psychiatry and individualised maintenance therapy to prevent relapse.

Psilocybin, a serotonergic psychedelic, can produce rapid and enduring antidepressant effects in patients with major depressive disorder (MDD)[1, 2], yet the neural mechanisms underlying these effects remain unclear. Negative affective biases are an important neuropsychological mechanism central to the development and perpetuation of MDD[3]. Using a translational rodent model, we previously demonstrated that psilocybin modulates negative affective biases which, we hypothesize, contribute to its antidepressant effects[4]. Here, we identify the prelimbic subregion (PrL) of the rat medial prefrontal cortex (mPFC) as a key locus for the modulation of affective biases by psilocin, the active metabolite of psilocybin, and reveal a cell-type-specific bidirectional regulation of synaptic transmission. Psilocin selectively suppressed excitatory synaptic input to cortico-amygdala (CA) projection neurons, but enhanced excitatory transmission to other, putatively cortico-cortical, targets. Interestingly, suppression of the excitatory input to CA cells by psilocin, and modulation of affective biases by psilocybin, were both dependent on 5HT1A and 5HT2A receptor signaling. Consistent with the long-term therapeutic effects of rapidly acting antidepressants[1, 2, 4, 5], psilocin produced sustained changes to affective biases evident 24 hours after PrL infusion. In parallel, the suppressed excitatory transmission shifted to enhanced inhibitory synaptic input selectively in CA cells. Finally, chemogenetic inhibition of CA neurons in PrL recapitulated both the acute and sustained modulation of negative affective biases by psilocybin, as well as positively biasing new reward memories. Together, these findings identify modulation of the PrL cortico-amygdala circuit as a key substrate for affective bias modification by psilocybin, an effect which could explain its rapid and sustained antidepressant actions.

Opioid use disorder occurs alongside impaired risk-related decision-making, but the underlying neural correlates are unclear. We developed an approach-avoidance conflict task using a modified conditioned place preference procedure to study neural signals of risky opioid seeking in the prefrontal cortex, a region implicated in executive decision-making. Following morphine conditioned place preference, rats underwent a conflict test in which fear-inducing cat odor was introduced in the previously drug-paired side of the apparatus. While the saline-exposed control group avoided cat odor, the morphine group included two subsets of rats that either maintained a preference for the paired side despite the presence of cat odor (Risk-Takers) or exhibited increased avoidance (Risk-Avoiders), as revealed by K-means clustering. Single-unit recordings from the prelimbic cortex (PL) demonstrated decreased neuronal activity upon acute morphine exposure in both Risk-Takers and Risk-Avoiders, but this firing rate suppression was absent after repeated morphine administration. Risk-Avoiders also displayed distinct post-morphine excitation in PL which persisted across conditioning. During the preference test, subpopulations of PL neurons in all groups were either excited or inhibited when rats entered the paired side. Interestingly, the inhibition in PL activity was lost during the subsequent conflict test in both saline and Risk-Avoider groups, but persisted in Risk-Takers. Additionally, Risk-Takers showed an increase in the proportion of PL neurons displaying location-specific firing in the drug-paired side from the preference to the conflict test. Together, our results suggest that persistent PL inhibitory signaling in the drug-associated context during motivational conflict may underlie increased risk-taking behavior following opioid exposure. SIGNIFICANCE STATEMENTRisky opioid use is well established in opioid use disorder, but the underlying neural correlates are poorly understood. In this study, we present findings from a novel behavioral task in which rats face a motivational conflict between contextual opioid reward memory and a naturalistic predator threat. Performing neuronal recordings in the prelimbic prefrontal cortex (PL), a brain region critical for executive decision-making, we demonstrate enhanced representation of drug-associated context and persistent inhibitory signaling by PL neurons that occur alongside opioid-induced risk-taking behavior. Our findings refine a preclinical model for studying addiction, establish PL as a prime region for investigating drug-environment interactions, and positions the prefrontal cortex as a candidate region for translational studies targeting risky opioid use.

The effect of low doses (<=20 g) of LSD on working memory, in the absence of altered states of consciousness, remain largely unexplored. Given its possible effects on serotonin 5-HT2A receptors and dopaminergic signalling, it could be hypothesised that LSD microdoses modulate working memory recall. Moreover, in line with computational models, LSD microdoses could exert antagonistic effects on distracter resistance and updating. Here, we tested this hypothesis in a randomised double-blind, placebo-controlled study comparing three different LSD microdoses (5 g, 10g and 20g) with placebo. After capsule administration, participants performed a modified delay-match-to-sample (DMTS) dopamine-sensitive task. The standard DMTS task was modified to include novel items in the delay period between encoding and probe. These novel items either had to be ignored or updated into working memory. There was no evidence that LSD microdoses affected the accuracy or efficiency of working memory recall and there was no evidence for differential effects on ignoring or updating. Due to the small sample of participants, these results are preliminary and larger studies are required to establish whether LSD microdoses affect short-term recall.

Opioid misuse remains rampant as new synthetic opioids reach the market. Large-scale genetic tools like the GWAS identify previously unrecognized targets and biomarkers in opioid misuse with hopes of combating the opioid epidemic. One such target is the AMPAR auxiliary protein Cornichon Homolog-3 (human analog: CNIH3, mouse analog: Cnih3), which determines AMPAR subunit composition and kinetics. Though CNIH3 was identified as a gene of interest in OUD, its role in opioid use and accompanying risk factors has not been studied. Using mice with Cnih3 deletion, we assess the role of CNIH3 in risk factors for opioid use, cognition, and opioid use itself. We find that Cnih3 deletion moderately impairs spatial memory, reward-cue association, and reversal learning. Cnih3 deletion also impairs fentanyl-cue association and blunts fentanyl intake during IVSA. We use principal component analysis to pinpoint the dimensions in which Cnih3 deletion impacts behavior in an unbiased manner. Additionally, we identify in previously published human data that single-nucleotide polymorphisms are more protective against progression to daily opioid use in women than in men, suggesting a potential sex-specific role of CNIH3. These findings highlight an important role of CNIH3 in opioid use through learning and memory processes that may differ between males and females.

Despite decades of clinical implementation of medications for opioid use disorder (OUD), overdose mortality rates remain high, underscoring a critical gap in treatments that target brain mechanisms driving addiction. Mindfulness-Oriented Recovery Enhancement (MORE) has demonstrated efficacy in reducing opioid use and craving, hypothetically by restructuring the salience of drug and natural rewards. Yet, to date, MOREs neurobiological mechanisms remain unclear. In this first functional magnetic resonance imaging (fMRI) randomized controlled trial (RCT) of MORE for OUD (NCT04112186), we tested whether compared with an active psychoeducational supportive therapy (PST) control group, MORE rebalanced neural responses to drug and natural reward cues in inpatients with OUD receiving standard of care including medications. Compared with PST, eight weeks of MORE significantly reduced drug-biased activity in the dorsolateral prefrontal cortex (dlPFC) and posterior regions of the default mode network including the precuneus during downregulation of responses to drug cues relative to upregulation of responses to natural reward cues (even when controlling for passive cue viewing). The shift from drug to natural reward responses in the lateral and ventromedial PFC was associated with lower cue-induced craving exclusively in the MORE group. MORE also reduced medial PFC synchronization to naturalistic drug-related movie scenes and significantly extended abstinence duration at follow-up ([~]4 months post-treatment) relative to PST. Together, this neuroimaging RCT demonstrates that MORE normalizes function in PFC nodes of the reward, salience, and control systems, positioning MORE as a biologically-grounded adjunct to pharmacotherapy for OUD.

The growing perception of cannabinoids as benign has increased perinatal exposure to both {Delta}9-tetrahydrocannabinol (THC) and cannabidiol (CBD), yet their long-term effects on prefrontal circuitry remain incompletely defined. Here we used whole-cell and field electrophysiology in adult mice (P100-140) of both sexes to compare how in utero exposure to THC or CBD (GD5-18) remodels layer-5 pyramidal neurons in the medial prefrontal cortex (mPFC). We quantified intrinsic excitability, excitatory and inhibitory synaptic transmission, the net E/I ratio, spontaneous excitatory and inhibitory currents kinetics, and canonical forms of synaptic plasticity (endocannabinoid-mediated LTD and NMDA-dependent LTP). Both cannabinoids shifted the adult mPFC toward a more pro-excitatory state: the E/I ratio was altered in a compound- and sex-dependent manner, and endocannabinoid-mediated LTD was abolished across groups. THC recapitulated previously reported deficits, producing male-specific increases in intrinsic excitability and accelerating excitatory current kinetics in females, demonstrating a conserved cross-species vulnerability of prefrontal circuits to gestational THC. CBD produced distinct signatures: female offspring showed marked increases in spontaneous excitatory event frequency and amplitude, indicating large-scale reorganization of excitatory and inhibitory inputs, while male offspring exhibited a selective and profound impairment of LTP. The combination of universal eLTD loss and CBD-specific LTP impairment in males yields a bidirectional loss of plasticity: an emergent synaptic rigidity in which circuits are unable to potentiate or depress effectively. Together, these convergent and divergent effects establish that prenatal exposure to THC and CBD produces lasting, sex-dependent rewiring of mPFC circuitry. Our results caution that the non-intoxicating profile of CBD does not preclude durable developmental impact and underscore the importance of considering both compound identity and sex when assessing the neurodevelopmental risks of perinatal cannabinoid exposure.

Chemogenetic studies using Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) enable the precise manipulation of neuronal activity in specific brain regions and cell types. DREADDs are widely used to dissect neural circuits underlying animal behavior, including learning and memory. Clozapine-N-Oxide (CNO), a metabolite of clozapine and one of the earliest-developed ligands for muscarinic DREADDs, was initially considered pharmacologically inert. However, CNO is now known to undergo back-metabolism to clozapine, leading to undesired off-target behavioral effects, including alterations in locomotion and anxiety-related behaviors. New ligands such as Compound 21 (C21) have been developed to improve selectivity and reduce these effects. However, despite their widespread use, no studies to date have directly compared the effects of CNO and C21 themselves on specific cognitive processes such as hippocampus-dependent memory formation. Here, we measured acute effects of CNO and C21 on spatial memory encoding, using an object-location memory (OLM) paradigm in male and female mice. We also quantified encoding-associated hippocampal principal neuron and parvalbumin (PV+) interneuron activity by measuring cFos expression in these populations. Across dorsal hippocampal subregions, neither ligand altered overall neuronal activity nor PV+ interneuron activity during encoding. Nonetheless, we find that CNO administration impairs OLM encoding, while C21 does not. Together, these findings highlight a previously unrecognized behavioral effect of CNO administration on hippocampus-dependent memory formation--even in the absence of DREADD expression--and indicate that C21 may be a preferable ligand for chemogenetic studies examining memory and hippocampal function.

Opioid addiction is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative affective states and anhedonia-driven behaviors. In addition to the current epidemic that was declared in the U.S.A., opioid-related deaths are increasing in other countries around the world. Classical antidepressants, or the currently prescribed opioid substitution pharmacotherapies have limited efficacy to reverse maladaptive behavioral responses, negative affect or prevent relapse in opioid abstinent individuals. Here, by establishing and using novel mouse models for the study of opioid addiction, we demonstrate, for the first time, the therapeutic potential of ketamines metabolite, (2R,6R)-hydroxynorketamine (HNK). In particular, our studies showcase (2R,6R)-HNKs ability to reverse conditioning to sub-effective doses of morphine in stress-susceptible mice, prevent conditioned-place aversion and mitigate acute somatic withdrawal symptoms in opioid-dependent animals. In addition, we show that this metabolite reverses anhedonia, anxiety-like behaviors, cognitive impairment, and general stress susceptibility associated with protracted opioid withdrawal, thereby presenting a promising therapeutic avenue for opioid relapse prevention. Our results strongly suggest that (2R,6R)-HNK, potentially by augmenting downstream brain-derived neurotrophic factor (BDNF) and GluN2A N-methyl-D-aspartate receptor signaling, effectively reverses maladaptive behavioral responses typical of protracted opioid abstinence. Furthermore, it facilitates the extinction of opioid conditioning and prevents stress-induced reinstatement of opioid-seeking behaviors. Our findings highlight how (2R,6R)-HNK, through an enhancement of synaptic plasticity in mood-regulating brain areas, has the potential to be an effective, next-generation pharmacotherapy for opioid use disorders by addressing emotional disturbances associated with protracted abstinence. SIGNIFICANCE STATEMENTOur studies represent a comprehensive exploration into the critical facets of opioid addiction and abstinence, offering critical insights into the significant potential of (2R,6R)-HNK as a treatment for this disorder. By unraveling the complex dynamics of opioid withdrawal and addressing the profound emotional disturbances underlying relapse vulnerability, our findings illuminate a promising innovative avenue for therapeutic intervention. The demonstrated ability of (2R,6R)-HNK to reverse maladaptive behaviors emerging during protracted opioid abstinence, facilitate extinction of opioid conditioning, prevent stress-induced reinstatement, represents a paradigm shift in addiction research. These revelations not only deepen our comprehension of the neurobehavioral complexities associated with opioid abstinence but also underscore the profound implications of (2R,6R)-HNK as a prospective pharmacotherapy in mitigating the devastating impact of opioid use disorder, potentially transforming addiction treatment strategies.

Preclinical evidence suggests that modulating neural excitation through diazepam administration, a positive allosteric modulator of GABAA receptors, can prevent the emergence of behavioural and neurobiological alterations relevant to psychosis in adulthood. Here, we examined this neurochemical mechanism in individuals at clinical high-risk for psychosis (CHRp) in a randomised, double-blind, placebo-controlled crossover study. Twenty-four individuals aged 18-35 were scanned twice using proton magnetic resonance spectroscopy (1H-MRS) to measure anterior cingulate cortex (ACC) Glx (glutamate and glutamine) levels, once after a single dose of diazepam (5 mg), and once after placebo. Mixed-effects model analyses revealed that diazepam reduced ACC Glx levels compared to placebo (t(20.8) = -2.14, p = 0.04). The effect of diazepam on Glx levels was greater in older CHRp individuals (t(12) = -4.36, p = 0.001). These findings suggest that pharmacological modulation of GABAA receptors can alter glutamatergic changes in psychosis.

Serotonergic psychedelics are known for their profound effects on consciousness and are gaining renewed interest as potential psychiatric treatments. These advances underscore the need to clarify the mechanisms of action of these compounds. This systematic review compiles and critically evaluates 23 in vitro and 26 in vivo electrophysiological studies on psychedelic compounds, with an emphasis on layer 5 pyramidal neurons in the prefrontal cortex, where 5-HT2A receptors are densely expressed. Our findings reveal that psychedelics exert complex, heterogeneous effects on neuronal excitability, synaptic transmission, and local oscillations. These results challenge the simplified view that psychedelics uniformly increase cortical excitability. Instead, they modulate both excitatory and inhibitory processes in a cell-type- and compartment-specific manner, with evidence for biphasic, dose-dependent, and context-sensitive responses. Activation of 5-HT2A receptors leads to intricate calcium signaling, downregulating excitatory currents and firing rates in many neurons, while enhancing glutamate release and activating a subset of projection fibers. Modulation of presynaptic and extrasynaptic GluN2B-containing NMDA receptors appears central to these effects, and some indirect evidence supports the involvement of intracellular 5-HT2A receptors. These insights prompt a reassessment of prevailing models of psychedelic action and underscore the value of incorporating electrophysiological data into psychedelic neuropharmacology.

Adolescent cannabis use increases the risk for cognitive impairments and psychiatric disorders. Cannabinoid receptor type 1 (Cnr1) is expressed not only in neurons and astrocytes, but also in microglia, which shape synaptic connections during adolescence. Nonetheless, until now, the role of microglia in mediating the adverse cognitive effects of delta-9-tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis, has been unexplored. Here, we report that adolescent THC exposure produces microglial apoptosis in the medial prefrontal cortex (mPFC), which was exacerbated in the mouse model of 16p11.2 duplication, a representative copy number variation (CNV) risk factor for psychiatric disorders. These effects are mediated by microglial Cnr1, leading to reduction in the excitability of mPFC pyramidal-tract neurons and deficits in social memory in adulthood. Our findings highlight the importance of microglial Cnr1 to produce the adverse effect of cannabis exposure in genetically vulnerable individuals.

Nearly one third of women of reproductive age in the United States are prescribed opioids annually; 14% of women fill an opioid prescription during pregnancy, and one in five report misuse. Opioid use during pregnancy has given rise to an increasing population of infants born with gestational opioid exposure. Although substantial clinical work has focused on treating these infants as they experience opioid withdrawal symptoms at the time of birth, notably few studies have examined the effects of gestational opioid exposure on brain development and long-term cognitive function. During typical brain development, endogenous opioids and their receptors are highly expressed by neural progenitor cells, neurons, and glia where they modulate cell proliferation, differentiation, and maturation. Thus, any disruption to the endogenous opioid system during the critical period of brain development may have lasting consequences on brain cell populations and the behaviors they influence. Indeed, opioid-exposed infants have smaller brains than age-matched peers and show significant neurodevelopmental impairment; they also have higher rates of learning disability at school age. To investigate how exposure to exogenous opioids during brain development affects neural maturation in the hippocampus, a brain region critical for learning and memory, our lab has developed a clinically relevant perigestational morphine exposure rat model. The current study reports that perigestational exposure to morphine delays postnatal hippocampal neuronal maturation, alters astrocyte and oligodendrocyte proliferation, and alters expression of brain-derived neurotrophic factor (BDNF), a protein crucial for healthy brain growth. Furthermore, we show that environmental enrichment rescues BDNF deficits, offering evidence for the effectiveness of non-invasive, non-pharmacological intervention for developmental consequences of perigestational opioid exposure.

Cannabis use is an increasingly common therapeutic for a variety of chronic diseases. In addition, people with sleep problems may self-medicate using cannabis products. However, genetic architecture of cannabis use and its shared genetic predispositions with sleep traits has not been systematically examined. We performed a meta-analysis of cannabis use within the All of Us and UK Biobank cohorts, consisting of 152,807 cases and 220,272 controls. Our meta-analysis identified 39 independent loci, including the previously reported CADM2 locus associated with cannabis use and replicating previous work. Additionally our associations include neuronal and sleep-regulating genes such as HTR1A, RAI1, SLC39A8, and NCAM1. Moreover, tissue-specific analyses revealed that the genetic architecture of cannabis use is heavily enriched within the central nervous system and specific brain cell types. In addition, we observed significant positive genetic correlations with clinical insomnia, insomnia-related medication usage, and objectively measured nighttime physical activity, alongside negative correlations with morningness chronotype and daytime activity. Fine-mapping and colocalization analyses identified shared genetic signals between cannabis use and clinical insomnia including a near-perfect colocalization at SLC39A8 and CADM2. Together, these results highlight the shared genetic risk between cannabis use and sleep disorders. Additionally, our findings indicate the importance of investigating the genetic effects of cannabis use as its use becomes more widespread, both recreationally and medicinally.

Biological sex as a defining variable in drug sensitivity remains poorly understood. Here, we combine behavioral and electrophysiological analyses to examine the influence of sex and gonadal hormones on cocaine-induced psychomotor sensitization and nucleus accumbens shell (NAcSh) plasticity in the prominent C57BL/6J mouse strain. Males exhibited greater cocaine-evoked locomotor activity than females; castration attenuated responses, whereas ovariectomy enhanced them. This behavioral phenotype is opposite to what occurs in rats. A 10-14 day abstinence period abolished the sex difference in intact animals, and gonadectomy reduced cocaine-induced behavioral plasticity. Recordings from 309 medium spiny neurons revealed sex-dependent NAcSh plasticity. In males, cocaine decreased neuronal excitability, while in females it induced estrous cycle-dependent plasticity characterized by reduced excitability during diestrus relative to estrus. These effects were driven by cocaine-induced modulation of voltage-gated sodium channels. Cocaine potentiated glutamatergic strength in males but elicited estrous cycle-dependent depotentiation in females. These adaptations in excitability and glutamatergic strength were abolished by gonadectomy, and paralleled diminished behavioral plasticity during abstinence. These data illustrate that biological sex and hormonal milieu critically shape cocaine-induced plasticity, offering a more nuanced framework than the traditional notion of heightened female sensitivity to drugs of abuse.

Corollary discharge (CD) signals allow the brain to predict and suppress the sensory consequences of its own actions, providing stability to perception and thought. Disruption of these predictive mechanisms has long been hypothesized to contribute to the disorganization of experience in schizophrenia, yet direct circuit-level evidence has been lacking. Here, we show that ketamine, a dissociative N-methyl-D-aspartate receptor (NMDAR) antagonist, at subanesthetic doses, selectively disrupts CD signaling in the lateral prefrontal cortex (LPFC)--a region thought to be the seed of mental representations and one of the most affected areas in schizophrenia. We recorded activity from 1,342 neurons in LPFC areas 8a and 9/46 of macaques performing a visuospatial working-memory task in a virtual environment, before and after subanesthetic ketamine administration. Ketamine impaired performance and increased overall firing rates but markedly suppressed saccade-related responses carrying CD signals. This led to decreased discriminability of eye movement signals. This finding links two major ideas in neuroscience research: the role of disrupted glutamate signaling and the failure of the brains predictive models. It provides evidence for how these mechanisms may interact in the prefrontal cortex to disturb the sense of reality.